Notably, the levels of both lncRNAs are higher in invasive breast cancers expressing mutant p53, a potent inhibitor of TAp63 function3, thus making our findings relevant for a large percentage of breast cancer patients (37% of all cases, up to 80% in the basal-like subtype11) and possibly for other tumour types harbouring TP53 mutations. The gene discussed is TP53; the disease is invasive breast carcinoma.